AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03682705
Drug: Elsubrutinib
RxNorm normalized name: Elsubrutinib
DrugBank: Elsubrutinib (DB18850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elsubrutinib capsule will be administered orally.
Trial: NCT00874562
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taken orally mixed with water or orange juice
Trial: NCT00207727
Drug: CNTO 1275
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03682705
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib tablet will be administered orally.
Trial: NCT03759366
Drug: Eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eculizumab will be administered by IV infusion.
Trial: NCT00732680
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
Trial: NCT03526926
Drug: CPX-351
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.
Trial: NCT02753075
Drug: Fluoride toothpaste
RxNorm normalized name: sodium fluoride Toothpaste
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate
Trial: NCT01237977
Drug: Botulinum Toxin Type A(Meditoxin®)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: single administration, Day 0, 20U
Trial: NCT01237977
Drug: Botulinum Toxin Type A(Botox®)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: single administration, Day 0, 20U
Trial: NCT00071968
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02109172
Drug: TD-4208
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03682705
Drug: Placebo for elsubrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule for elsubrutinib will be administered orally.
Trial: NCT03682705
Drug: Placebo for upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo tablet for upadacitinib will be administered orally.
Trial: NCT00265330
Drug: Ziprasidone oral capsules
RxNorm normalized name: ziprasidone Oral Capsule
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
Trial: NCT02283489
Drug: recombinant human endostatin adenovirus
RxNorm normalized name: Human adenovirus b serotype 7
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).~Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study.
Trial: NCT02283489
Drug: Cisplatin injection
RxNorm normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.
Trial: NCT02283489
Drug: Paclitaxel injection
RxNorm normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
Trial: NCT00210327
Drug: Bortezomib (drug)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02173730
Drug: BIBR 1048 MS
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBR 1048 MS capsule 150 mg
Trial: NCT02173730
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pantoprazole tablet 40 mg
Trial: NCT01576718
Drug: Fp MDPI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening.
Trial: NCT01576718
Drug: Flovent Diskus
RxNorm normalized name: Flovent Diskus
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
Trial: NCT01576718
Drug: albuterol/salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Trial: NCT02478125
Drug: Burixafor Hydrobromide
RxNorm normalized name: hydrobromic acid
DrugBank: Burixafor (DB11970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF
Trial: NCT02478125
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2
Trial: NCT02478125
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
Trial: NCT00595972
Drug: ECF-endostar
RxNorm normalized name: Menostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Trial: NCT00847977
Drug: use of a non balced fluid and of a macromolecular fluid
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological serum: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Heafusine: boli 10 ml/kg on 20 minutes
Trial: NCT00847977
Drug: use of balanced crystalloids fluid and macromolecular fluid
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes
Trial: NCT04645303
Drug: hyaluronic acid (20 mg/2 mL)
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A1-Pulley infiltration for trigger finger
Trial: NCT04645303
Drug: Triamcinolone acetonide 10mg/ml
RxNorm normalized name: TRIAMCINOLONE ACETONIDE 10MG/ML INJ,SUSP
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A1-Pulley infiltration for trigger finger
Trial: NCT03840993
Drug: MT-2990
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: over 16 weeks
Trial: NCT00551954
Drug: acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg (tablets) t.i.d.
Trial: NCT02788708
Drug: Lenvatinib Mesylate
RxNorm normalized name: Lenvatinib Mesylate
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02788708
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01602900
Drug: Rolipram
RxNorm normalized name: Rolipram
DrugBank: Rolipram (DB01954)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Challenge Agent
Trial: NCT04148963
Drug: Inhaled loxapine
RxNorm normalized name: loxapine Inhalant Product
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
Trial: NCT02233699
Drug: XEN-D0501
RxNorm normalized name: XEN-D0501
DrugBank: XEN-D0501 (DB18673)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00372632
Drug: Sulfadoxine-Pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
Trial: NCT00004250
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00441168
Drug: adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
Trial: NCT00441168
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
Trial: NCT00441168
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
Trial: NCT00441168
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vincristine: 0.4mg IV push on days 1 to 4
Trial: NCT03644771
Drug: Acthar
RxNorm normalized name: Acthar
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 treatment periods of 3 months each with 20 units biweekly, 40 units biweekly, and 80 units biweekly, with a tapering period to no drug for the fourth 3 month period. Then one year f/u.
Trial: NCT00402337
Drug: linaclotide acetate
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral, once daily.
Trial: NCT02285504
Drug: SAGE-547
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT01779492
Drug: Oxycontine CR 10mg
RxNorm normalized name: Oxycontin
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: twice a day
Trial: NCT03071172
Drug: Triptorelin for Injection
RxNorm normalized name: triptorelin Injection
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Trial: NCT03071172
Drug: Recombinant Human Choriogonadotropin alfa Solution for Injection
RxNorm normalized name: Choriogonadotropin Alfa
DrugBank: Choriogonadotropin alfa (DB00097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Trial: NCT03071172
Drug: Progesterone Soft Capsules
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Trial: NCT02043652
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
Trial: NCT02043652
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
Trial: NCT02016365
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/day (500 mg +250mg orally) continuously
Trial: NCT01729104
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I.
Trial: NCT01729104
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
Trial: NCT01416155
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00475514
Drug: Frovatriptan 2.5mg QD
DrugBank: Frovatriptan (DB00998)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00475514
Drug: Frovatriptan 2.5 mg BID
DrugBank: Frovatriptan (DB00998)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00624650
Drug: Diuresis (furosemide) part I
RxNorm normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal: Overall I/O net negative 50ml/hour~Initiation:~1. Continuous IV furosemide at 3mg/hour or last known protocol specified dose~2. Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal~3. Do not exceed 30mg/hour~Furosemide Bolus:~1. If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows~2. By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour~3. Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period
Trial: NCT00624650
Drug: Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (may use any alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.
Trial: NCT00624650
Drug: Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (may use alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.~In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of \< 60
Trial: NCT00624650
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.~Used in patients with a measured cardiac index \< 2.5
Trial: NCT00624650
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.
Trial: NCT00624650
Drug: Diuresis (furosemide) part II
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Withhold furosemide if:~1. Significant hypokalemia (K+ \<= 2.5 meq/L), or hypernatremia (Na+ \>= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~2. Dialysis dependence~3. Oliguria (less than 0.5ml/kg/hour) with either creatinine \> 3, or clinical suspicion of rapidly evolving ARF~4. More than 800mg has been given in less then 24 hours~5. Creatinine increases \> 1.5 mg/dl in any 24 hour period
Trial: NCT03755518
Drug: FEDRATINIB
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A potent and selective inhibitor of JAK2 kinase activity
Trial: NCT02596217
Drug: ABBV-066
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT02596217
Drug: ABBV-066
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT01843049
Drug: Chemotherapy (5-FU+DDP)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
Trial: NCT02009332
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine is administered after ABI-009 in the Phase 2 study.
Trial: NCT01075854
Drug: Gonal-F (Follitropin alfa)
RxNorm normalized name: follitropin alfa Injection [Gonal F]
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin alfa FbM solution for injection in a prefilled pen is available in three strengths: 300 IU/0.5 ml (22 µg/0.5 ml), 450 IU/0.75 ml (33 µg/0.75 ml) and 900 IU/1.5 ml (66 µg/1.5 ml). The starting dose is usually recommended to be between 150 and 300 IU. The dose is then adjusted according to the ovarian response.
Trial: NCT01729104
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
Trial: NCT01714609
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib, 400 mg twice daily
Trial: NCT01464190
Drug: Sevelamer carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
Trial: NCT00795639
Drug: Sitaxsentan
RxNorm normalized name: Sitaxsentan
DrugBank: Sitaxentan (DB06268)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sitaxsentan = 100 mg tablet administered orally, once daily
Trial: NCT02732327
Drug: CAZ-AVI
RxNorm normalized name: CAZ
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime-Avibactam (2 g ceftazidime and 0.5 g avibactam)